ALKS Alkermes plc

33.43
+0.86  (+3%)
Previous Close 32.57
Open 32.11
Price To Book 4.51
Market Cap 5194446569
Shares 155,382,787
Volume 828,350
Short Ratio
Av. Daily Volume 891,063

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Schizophrenia
Phase 3 data due early 2020.
ALKS 3831 - ENLIGHTEN-Early
Schizophrenia - young adults
Phase 3 data released November 29, 2018 met co-primary endpoints. NDA filing due mid-2019.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada
Schizophrenia
NDA filing announced December 17, 2018.
ALKS 8700 (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
CRL announced February 1, 2019.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia
Phase 1 initial data at SITC November 9, 2018.
ALKS 4230
Solid tumors
Phase 3 data due 1H 2019.
Aristada and Invega Sustenna
Schizophrenia

Latest News

  1. CLASS ACTION UPDATE for ALKS, MU, SVXY and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  2. DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline - February 25, 2019
  3. Alkermes Public Limited Company Reminder: Pawar Law Reminds of Important February 25, 2019 Lead Plaintiff Deadline in Class Action – ALKS
  4. CLASS ACTION UPDATE for DBVT, AXGN, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  5. Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS)
  6. DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  7. CLASS ACTION UPDATE for IMMU, ALKS, UXIN and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  8. Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) & DXC Technology Company (DXC) - Bronstein, Gewirtz & Grossman, LLC Class Action Update
  9. CLASS ACTION UPDATE for PRGO, DBVT, ALKS and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  10. CLASS ACTION UPDATE for AXGN, ALKS, GE and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  11. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline  – ALKS
  12. Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)
  13. CLASS ACTION UPDATE for IMMU, DBVT, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  14. The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
  15. CLASS ACTION UPDATE for ALKS, GSM, ASTE and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  16. 6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. ALKS UPCOMING FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important Deadline in Securities Class Action – ALKS